Novo and Lillys versions are currently protected by patents, meaning mass-produced generic versions arent yet available
For women specifically, our guides on peptides for weight loss in women , best peptides for women , and peptides for menopause weight loss address gender-specific considerations
The study also investigated recurrent AUD, in which patients with a history of AUD were assessed for relapse or recurrence
GLP-1 penetration increased nearly 10% between November 2025 and June 2026 The share of Americans who say they will never use a GLP-1 fell from 66.9% in June 2025 to 62.3% in June 2026 Forecasted food volume impact has increased to between 1.4% and 3.4% across CPG categories GLP-1 users continue to trade down to smaller package sizes at significantly higher rates than other consumers, including in cereal, chips, soft drinks, coffee, and granolaPack-size reductions are increasingly appearing outside traditional discretionary categories, suggesting broader effects across grocery aisles "The industry doesn't need to decide whether GLP-1s matter anymore
"Mechanisms of diabetic complications." Physiol Rev